Neal D. Shore, MD, FACS, presented “HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in June, 2020.
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer – Summary:
Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, presents the key aspects of the HERO phase 3 trial. The HERO trial looked at Relugolix, an oral GnRH receptor antagonist, versus Leuprolide Acetate for the treatment of advanced prostate cancer. He begins by going over the study design, patient demographics, and clinical characteristics. He then goes over some of the study’s key and secondary endpoints, all of which were met.
In this interview, Celestia S. Higano, MD, Professor of Medicine at the University of Washington School of Medicine and section editor of the ADT Next Generation Learning Center on Grand Rounds in Urology, asks Dr. Shore follow-up questions about the HERO trial’s findings, and the implications that this exciting new development in prostate cancer treatment could have in the field of urology.
How to cite: Shore, Neal D. “HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer” June, 2020. Accessed Nov 2024. https://grandroundsinurology.com/tmprss2-ace-2-and-the-potential-role-of-5aris-and-gnrh-analogues-in-inhibiting-covid-19-infection/
ABOUT THE AUTHOR
Neal D. Shore, MD, FACS, graduated from Duke University and Duke University Medical School. He completed his general surgery/urology residency at New York Hospital-Cornell Medical Center/Memorial Sloan Kettering Cancer Center. He serves as the Medical Director for the Carolina Urologic Research Center and is the Chief Medical Officer, Strategic Growth and Pharmacy, GenesisCare, US.
Dr. Shore has conducted more than 400 clinical trials, focusing mainly on genitourinary oncology, and has authored or coauthored more than 350 peer-reviewed publications and numerous book chapters. He serves on the Society for Immunotherapy of Cancer (SITC) Guidelines Committee for Bladder Cancer, as well as the boards of the Bladder Cancer Advocacy Network, Maple Tree Alliance, and the Duke Global Health Institute. He is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy for the Large Urology Group Practice Association (LUGPA) Specialty Network. He also co-chairs the annual AUA International Prostate Forum. He has served/serves on the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, JUOP and World Journal of Urology, and he also serves as an editor of Everyday Urology-Oncology. He is a Fellow of the American College of Surgeons.
